皓元医药
(688131)
| 流通市值：175.19亿 | | | 总市值：175.19亿 |
| 流通股本：2.12亿 | | | 总股本：2.12亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,310,942,751.62 | 606,125,018.69 | 2,270,177,811.5 | 1,619,063,344.9 |
| 营业收入 | 1,310,942,751.62 | 606,125,018.69 | 2,270,177,811.5 | 1,619,063,344.9 |
| 二、营业总成本 | 1,083,752,794.05 | 500,107,881.66 | 1,900,882,004.66 | 1,383,328,088.18 |
| 营业成本 | 667,674,761.08 | 311,648,334.05 | 1,181,279,071.54 | 848,692,363.99 |
| 税金及附加 | 6,413,450.95 | 2,972,567.81 | 13,251,425.49 | 8,711,014.25 |
| 销售费用 | 130,223,926.22 | 55,123,962.3 | 209,908,171.73 | 153,373,226.19 |
| 管理费用 | 145,848,900.37 | 67,836,339.46 | 234,994,900.01 | 175,472,795 |
| 研发费用 | 116,902,479.74 | 53,713,674.32 | 226,932,038.19 | 172,412,405.7 |
| 财务费用 | 16,689,275.69 | 8,813,003.72 | 34,516,397.7 | 24,666,283.05 |
| 其中:利息费用 | 13,844,753.89 | 6,348,625.94 | 31,326,271.51 | 21,690,759.65 |
| 其中:利息收入 | 5,123,337.15 | 2,142,974 | 7,482,216.02 | 4,953,820.59 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 212,602.74 | - | 150,068.49 | - |
| 加:投资收益 | 1,247,313.04 | 1,329,224.95 | -13,757,656.87 | -5,034,621.27 |
| 资产处置收益 | 616,971.72 | 9,351.07 | -567,191.03 | -91,866.73 |
| 资产减值损失(新) | -60,966,824.59 | -29,845,261.8 | -131,359,593.72 | -77,892,250.97 |
| 信用减值损失(新) | -5,234,127.13 | -7,927,872.33 | -16,324,015.96 | -13,545,184.25 |
| 其他收益 | 21,658,012.47 | 5,310,017.89 | 29,379,959.17 | 18,589,528.22 |
| 四、营业利润 | 184,723,905.82 | 74,892,596.81 | 236,817,376.92 | 157,760,861.72 |
| 加:营业外收入 | 359,501.71 | 143,918.86 | 2,352,504.76 | 457,098.15 |
| 减:营业外支出 | 3,461,032.3 | 1,777,944.09 | 814,600.33 | 385,253.44 |
| 五、利润总额 | 181,622,375.23 | 73,258,571.58 | 238,355,281.35 | 157,832,706.43 |
| 减:所得税费用 | 32,926,087.92 | 12,080,277.92 | 40,425,246.77 | 17,053,051.02 |
| 六、净利润 | 148,696,287.31 | 61,178,293.66 | 197,930,034.58 | 140,779,655.41 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 148,696,287.31 | 61,178,293.66 | 197,930,034.58 | 140,779,655.41 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 151,761,472.63 | 62,384,400.02 | 201,590,085.66 | 143,347,970.22 |
| 少数股东损益 | -3,065,185.32 | -1,206,106.36 | -3,660,051.08 | -2,568,314.81 |
| 扣除非经常损益后的净利润 | 140,571,127.52 | 58,917,994.16 | 178,952,687.06 | 129,556,520.04 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.72 | 0.3 | 0.96 | 0.68 |
| (二)稀释每股收益 | 0.72 | 0.3 | 0.96 | 0.68 |
| 八、其他综合收益 | -2,272,927.51 | 200,385.54 | 22,673,517.39 | 14,035,099.29 |
| 归属于母公司股东的其他综合收益 | -2,272,927.51 | 200,385.54 | 22,673,517.39 | 14,035,099.29 |
| 九、综合收益总额 | 146,423,359.8 | 61,378,679.2 | 220,603,551.97 | 154,814,754.7 |
| 归属于母公司股东的综合收益总额 | 149,488,545.12 | 62,584,785.56 | 224,263,603.05 | 157,383,069.51 |
| 归属于少数股东的综合收益总额 | -3,065,185.32 | -1,206,106.36 | -3,660,051.08 | -2,568,314.81 |
| 公告日期 | 2025-08-29 | 2025-04-30 | 2025-03-28 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |